Your browser doesn't support javascript.
loading
Endocannabinoids in chronic migraine: CSF findings suggest a system failure.
Sarchielli, Paola; Pini, Luigi Alberto; Coppola, Francesca; Rossi, Cristiana; Baldi, Antonio; Mancini, Maria Luisa; Calabresi, Paolo.
Afiliación
  • Sarchielli P; Neurologic Clinic, Department of Medical and Surgical Specialties and Public Health, University of Perugia, Perugia, Italy. neuro.pg@tiscalinet.it
Neuropsychopharmacology ; 32(6): 1384-90, 2007 Jun.
Article en En | MEDLINE | ID: mdl-17119542
Based on experimental evidence of the antinociceptive action of endocannabinoids and their role in the modulation of trigeminovascular system activation, we hypothesized that the endocannabinoid system may be dysfunctional in chronic migraine (CM). We examined whether the concentrations of N-arachidonoylethanolamide (anandamide, AEA), palmitoylethanolamide (PEA), and 2-arachidonoylglycerol (2-AG) in the CSF of patients with CM and with probable CM and probable analgesic-overuse headache (PCM+PAOH) are altered compared with control subjects. The above endocannabinoids were measured by high-performance liquid chromatography (HPLC), and quantified by isotope dilution gas-chromatography/mass-spectrometry. Calcitonin gene-related peptide (CGRP) levels were also determined by RIA method and the end products of nitric oxide (NO), the nitrites, by HPLC. CSF concentrations of AEA were significantly lower and those of PEA slightly but significantly higher both in patients with CM and PCM+PAOH than in nonmigraineur controls (p<0.01 and p<0.02, respectively). A negative correlation was found between AEA and CGRP levels in CM and PCM+PAOH patients (r=0.59, p<0.01 and r=-0.65, p<0.007; respectively). A similar trend was observed between this endocannabinoid and nitrite levels. Reduced levels of AEA in the CSF of CM and PCM+PAOH patients may reflect an impairment of the endocannabinoid system in these patients, which may contribute to chronic head pain and seem to be related to increased CGRP and NO production. These findings support the potential role of the cannabinoid (CB)1 receptor as a possible therapeutic target in CM.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Endocannabinoides / Moduladores de Receptores de Cannabinoides / Trastornos Migrañosos Tipo de estudio: Diagnostic_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Neuropsychopharmacology Asunto de la revista: NEUROLOGIA / PSICOFARMACOLOGIA Año: 2007 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Endocannabinoides / Moduladores de Receptores de Cannabinoides / Trastornos Migrañosos Tipo de estudio: Diagnostic_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Neuropsychopharmacology Asunto de la revista: NEUROLOGIA / PSICOFARMACOLOGIA Año: 2007 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido